VITILIGO

This Phase 3 trial tests whether an ointment called MH004 can help restore skin color in people with non-segmental vitiligo. The study includes adolescents and adults aged 12 to 75 with facial vitiligo. Participants apply the ointment twice daily for 24 weeks, and researchers mea…

This study tests an experimental drug called LY4005130 in 60 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants receive either the drug or a placebo by IV every few weeks for 24 weeks. The goal is to see if the drug can reduce the …

This study tests an experimental drug called D-2570 in 160 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Participants take either D-2570 or a placebo pill once daily for 24 weeks, with an optional 24-week extension. The goal is to see if t…

This study tests whether taking a daily pill (ritlecitinib) plus twice-weekly narrowband UVB light therapy works better than the pill alone for vitiligo. About 56 adults with non-segmental vitiligo covering 4-60% of their body will take part. The main goal is to see how much skin…

This early-stage trial compares two treatments for limited vitiligo: microneedling with 5-fluorouracil (5FU) every two weeks versus a strong steroid cream applied twice daily. Forty participants aged 5 to 70 with vitiligo on 10% or less of their body will be treated for 12 weeks.…

This early-stage trial tests whether CGB-600 gel can safely reduce white patches from vitiligo on the face and neck. Thirty-six adults will apply the gel or a placebo twice daily for 24 weeks. Researchers will check for side effects and measure if the patches shrink by at least 5…

This study tests a new effervescent (fizzing) powder containing 5-fluorouracil to treat vitiligo, a condition that causes white patches on the skin. Sixty people with stable vitiligo will apply either the new fizzing powder or plain 5-fluorouracil powder to their patches. The goa…

This study is testing a cream called ruxolitinib on 170 people with vitiligo, a skin condition that causes white patches. The goal is to find out what factors help the cream work best. Participants must be 12 or older and have mild to moderate vitiligo. They will stop other treat…

This study tests if using ultrasound (phonophoresis) to push betamethasone cream deeper into the skin can help control vitiligo, a condition that causes white patches. Researchers will enroll 60 adults with vitiligo who are otherwise healthy. The goal is to see if this approach r…

This early-stage trial tests a new drug called FB102 in 64 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Half will get the drug and half a placebo, both given by IV. The main goal is to check safety and see if the drug helps bring back ski…

This study tests a procedure where a person's own skin cells are transplanted onto stable white patches caused by vitiligo. The goal is to see how well and how safely it restores color over the long term. The trial will enroll 30 people with stable vitiligo who have not responded…

This study tests two ways of puncturing white patches of skin—using a single needle or a microneedling device—followed by UV light therapy to see which helps restore pigment better. Eighty adults with stable non-segmental vitiligo will receive six sessions over 24 weeks. The goal…

This observational study aims to collect and analyze data from up to two million patients with dermatologic conditions like vitiligo, atopic dermatitis, alopecia areata, and hidradenitis suppurativa, as well as their healthcare providers. By reviewing treatment patterns, outcomes…

This study looks at the bacteria living on the skin and in the gut of 100 adults with and without vitiligo. Researchers want to see if people with active or stable vitiligo have different bacteria compared to healthy volunteers. No treatments or drugs are given—just samples colle…